Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

December 01, 2015 4:08 PM ET

Life Sciences Tools and Services

Company Overview of Rubicon Genomics, Inc.

Company Overview

Rubicon Genomics, Inc. engages in the development and commercialization of sample-specific nucleic acid library preparation products for use in research and clinical testing on next-generation sequencing (NGS), microarray, and q-PCR platforms. The company creates molecular biology tools for genetic, epigenetic, and expression analysis of various samples to facilitate gene-based research, drug development, and diagnostics. Its products include ThruPLEX DNA-seq kits to generate DNA libraries with expanded multiplexing capability and diversity with lower duplication rates; PicoPLEX DNA-seq kits to streamline library preparation and PicoPLEX process used by IVF clinics for pre-implantation genet...

4743 Venture Drive

Ann Arbor, MI 48108

United States

Founded in 2000





Key Executives for Rubicon Genomics, Inc.

Chairman, Chief Executive Officer and President
Age: 66
Co-Founder and Chief Scientific Officer
Chief Financial Officer
Chief Operating Officer
Vice President of Business Development
Compensation as of Fiscal Year 2015.

Rubicon Genomics, Inc. Key Developments

Rubicon Genomics Announces Eurofins Scientific to Distribute its Suite of DNA Library Preparation Kits in U.S

Rubicon Genomics, Inc. announced an agreement with Eurofins Genomics for U.S. distribution of its DNA library preparation products, including the ThruPLEX DNA-seq kit and Rubicon's new ThruPLEX Plasma-seq kit. ThruPLEX Plasma-seq has been optimized for cell-free DNA to enable the preparation of NGS libraries for liquid biopsies-the analysis of cell-free circulating DNA in plasma for diagnostic and prognostic applications in cancer and other conditions. Liquid biopsies can eliminate the need for invasive and costly tissue biopsies to detect biomarkers and other genetic mutations in tumors. They are expected to transform cancer screening, diagnostics and treatment and to replace many prenatal amniocentesis procedures. ThruPLEX Plasma-seq kits enable liquid biopsies by producing highly reproducible next-generation sequencing (NGS) libraries from small amounts of cell-free DNA in plasma, enabling accurate and informative results from samples that might otherwise be difficult or impossible to analyze. ThruPLEX Plasma-seq libraries are suitable for whole genome, whole exome and targeted gene sequencing. The performance of the ThruPLEX Plasma-seq kit has been validated by researchers at the Karolinska Institute in Sweden and Cancer Research UK (CRUK). ThruPLEX Plasma-seq can now be easily automated for high throughput applications on Beckman Coulter's Biomek FXP Liquid Handling Workstation, a leading automated solution for laboratories worldwide. ThruPLEX DNA-seq works with as little as 50 picograms of DNA and is especially efficient for challenging specimens. The entire workflow is performed in a single tube or well in about two hours and requires no purification steps or sample transfers. ThruPLEX DNA-seq produces uniform coverage and improves molecular complexity, yielding highly reproducible sequencing results.

Rubicon Genomics Reports Sales Results for the Year 2014

Rubicon Genomics, Inc. reported that sales increased 28% in 2014, fueled by new product introductions and new agreements with distributors in Europe, North Africa, North America and Asia.

Rubicon Genomics Adds New Global Distributors; Hires Karl Hecker as Vice President of Product Development

Rubicon Genomics, Inc. announced that it has signed agreements with new distributors in Europe, North Africa and Asia to further expand the availability of its DNA library preparation products for arrays and Illumina(R) next-generation sequencing (NGS) platforms, including ThruPLEX(R) DNA-seq, PicoPLEX(TM) DNA-seq, and PicoPLEX WGA Kits. Rubicon's new distributors include CliniSciences in France, Spain and North Africa; Nerliens Meszansky AS in Norway; Shanghai Nanodigmnio Biotechnology Co., Ltd, in China; and GeneLabs Life Science in Taiwan. Rubicon announced that Karl Hecker, PhD, has joined the company as Vice President of Product Development. Dr. Hecker brings the Rubicon management team more than 15 years of life sciences and diagnostics product development expertise and over 25 years' experience in chemistry and molecular biology. At Invitrogen, he commercialized approximately 60 nucleic acid purification and isolation products in a three-year period.

Similar Private Companies By Industry

Company Name Region
Ionic Transport Assays Inc. United States
Immuneering Corporation United States
Absorption Systems, LP United States
Quanta BioSciences, Inc. United States
ScienceFirst, LLC United States

Recent Private Companies Transactions

Private Placement
July 15, 2015

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Rubicon Genomics, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at